FDA approves Genentech's Vabysmo prefilled syringe for wet AMD, DME, and RVO vision loss.
FDA approves Genentech's Vabysmo prefilled syringe for three leading causes of vision loss, including wet AMD, DME, and RVO. Genentech, a Roche Group member, develops the 6.0 mg single-dose prefilled syringe for treating these conditions, which affect nearly 3 million people in the US. The FDA approval comes as a relief for retina specialists and patients, who can expect the Vabysmo PFS to become available in the coming months.
July 05, 2024
3 Articles